7Baggers
 RBC Capital Lowers Price Target on Pliant Therapeutics (PLRX) |  GuruFocus Fri, 07 Nov 2025 20:08:43 GMT
 Needham Maintains Pliant Therapeutics(PLRX.US) With Hold Rating  富途牛牛 Fri, 07 Nov 2025 08:00:00 GMT
 pliant therapeutics reports improved q3 2025 results  TipRanks Fri, 07 Nov 2025 05:55:32 GMT
 Pliant Therapeutics (PLRX) Advances Portfolio Amid Strategic Tra  GuruFocus Fri, 07 Nov 2025 00:31:25 GMT
 pliant therapeutics reports q3 eps (43c), consensus (52c)  TipRanks Thu, 06 Nov 2025 23:59:18 GMT
 Pliant Therapeutics Reports Improved Q3 2025 Results  TipRanks Thu, 06 Nov 2025 08:00:00 GMT

Pliant Therapeutics, Inc
(NASDAQ:PLRX) 

PLRX stock logo

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of av6 and ...

Founded: 2015
Full Time Employees: 70
CEO: Bernard Coulie  
Sector: Healthcare
Industry: Biotechnology

Share this website to your friends